Pyxis Oncology Appoints Thomas Civik as CEO and Chairman

What Happened
Pyxis Oncology, Inc. (PYXS) filed an 8-K on September 8, 2026 reporting that on September 4, 2026 the Board appointed Thomas Civik (age 57) — previously Interim CEO since February 2, 2026 and a board member since September 2021 — as permanent Chief Executive Officer and Chairman of the Board. The company also announced related compensation and equity arrangements and made board leadership changes, including appointment of John Flavin as Lead Independent Director and Chair of the Compensation Committee. A press release announcing the appointment was furnished as Exhibit 99.1.

Key Details

• Base salary and bonus: Mr. Civik will receive an annualized base salary of $710,000 and an annual target bonus equal to 60% of base salary; 2026 bonus will be determined for his full period of 2026 service (not prorated).
• Sign-on cash: one-time $100,000 payment, repayable if Mr. Civik is terminated for Cause or resigns without Good Reason within six months.
• Equity grant: nonqualified stock option to purchase 2,503,050 shares, 10‑year term; vests 25% on first anniversary and the remaining 75% in 36 equal monthly installments (subject to continued employment). Acceleration provisions apply around a Change in Control or certain terminations.
• Severance: if terminated without Cause (or resigns for Good Reason) outside the Change in Control period, eligible for 12 months of base salary continuation and up to 12 months of COBRA; if termination occurs during the Change in Control period, eligible for a lump sum equal to 18 months of base salary plus 100% of target bonus and up to 12 months of COBRA.
• Board changes and resignation: roles of CEO and Chair combined; John Flavin moved to Lead Independent Director and Compensation Committee Chair; Dr. Santhosh Palani resigned effective Sept 4, 2026, and the Board immediately accelerated vesting of his unvested awards and extended his option exercise window.

Why It Matters
This 8-K signals a permanent leadership change and consolidation of CEO and Chair roles, which can affect company strategy and governance oversight. The transaction includes a sizable equity award (2,503,050‑share option) and cash/benefit protections that will be material to executive compensation expense, potential share dilution if exercised, and governance disclosures. Investors should note the date of the appointment (Sept 4, 2026) and the filing date (Sept 8, 2026) and may watch subsequent filings (e.g., the referenced amendment and Form 10‑Q) for the full agreements and additional details.